bims-imicid Biomed News
on Immunometabolism of infection, cancer and immune-mediated disease
Issue of 2026–11–15
57 papers selected by
Dylan Gerard Ryan, Trinity College Dublin



  1. Front Cell Infect Microbiol. 2026 ;16 1954451
      Paediatric refractory Mycoplasma pneumoniae pneumonia (RMPP) is a heterogeneous syndrome in which persistent microbial stimulation, dysregulated host immunity and evolving airway injury may coexist despite macrolide treatment. This review integrates clinical, experimental and multi-omics evidence to examine RMPP through an immunometabolic framework. Mycoplasma pneumoniae reprograms airway epithelial cells, macrophages and neutrophils by altering glycolysis, mitochondrial and redox signalling, autophagy and lipid and amino-acid metabolism. These responses can support early antimicrobial defence yet become maladaptive when inflammatory output is uncoupled from bacterial clearance. Epithelial ATP-dependent signalling, macrophage inflammasome activation, neutrophil aconitate decarboxylase 1 (ACOD1; historically termed immune-responsive gene 1 [IRG1])-itaconate activity and extracellular trap accumulation illustrate this context-dependent transition. Adaptive immune remodelling, compartment-specific Th17-regulatory T-cell imbalance and incomplete mucosal antibody protection may further sustain disease. Emerging metabolomic, lipidomic, microbiome and single-cell studies support biological heterogeneity but remain predominantly cross-sectional and cannot distinguish causal drivers from consequences of severe disease or treatment. Current mechanistic evidence is strongest for epithelial glycolysis and the neutrophil ACOD1-itaconate axis in experimental M. pneumoniae systems, whereas direct cell-resolved functional validation in paediatric RMPP remains limited, and ferroptosis and several proposed therapeutic targets remain provisional. We therefore present immunometabolic states as a hypothesis-generating framework rather than as validated endotypes. Future studies should determine whether dynamic combinations of pathogen burden, cell-specific metabolic function, inflammatory activity and anatomical injury reproducibly identify biological states that precede progression and predict differential treatment response. Longitudinal, cell-resolved studies integrating metabolic flux, pathogen trajectories, treatment exposure and anatomical evolution are required before these candidate states can support mechanism-informed clinical stratification.
    Keywords:  Mycoplasma pneumoniae pneumonia; immunometabolism; metabolic reprogramming; precision medicine; refractory pneumonia
    DOI:  https://doi.org/10.3389/fcimb.2026.1954451
  2. Front Immunol. 2026 ;17 1991331
      Psoriasis is a chronic, immune-mediated inflammatory dermatosis characterized by a profound dysregulation of immune-epithelial crosstalk. Beyond canonical ATP production, mitochondria function as essential intracellular immunometabolic hubs embedded within the cytokine-driven network of psoriatic lesions. Within this inflammatory niche, keratinocytes and immune cells undergo structural and metabolic adaptations. Aberrant mitochondrial stress byproducts-including mitochondrial reactive oxygen species (mtROS), oxidized mitochondrial DNA (mtDNA), and metabolic intermediates-act as secondary amplifiers that reinforce innate immune sensing and adaptive T cell responses, thereby sustaining a localized inflammatory loop. Here, we propose that targeting mitochondrial pathways provides a novel, stage-dependent therapeutic framework: stabilizing mitochondrial dynamics during acute flare-ups to halt inflammation, disrupting tissue-resident memory T (TRM) cell metabolic fitness during the stable phase to avert relapse, and restoring regulatory T (Treg) cell oxidative phosphorylation (OXPHOS) during regression to re-establish peripheral immune tolerance. Transitioning from broad immunosuppression to precision mitochondrial modulation offers a promising paradigm for cell-specific psoriasis interventions.
    Keywords:  Mitochondria; immunometabolism; mtROS; psoriasis; targeted metabolic therapy
    DOI:  https://doi.org/10.3389/fimmu.2026.1991331
  3. Front Immunol. 2026 ;17 1959305
      Immunometabolism provides a framework for understanding how metabolic cues shape immune cell fate and function. While traditionally centered on cell-intrinsic pathways, emerging evidence highlights a critical role for epithelial barrier regulation in shaping immune responses by controlling exposure to microbiome derived metabolites. Microbial metabolites including short-chain fatty acids, bile acid derivatives, tryptophan catabolites, and polyamines engage conserved metabolic checkpoints such as mTOR, AMPK, PPARs, SIRT1, and HIF-1α to influence immune activation, tolerance, and inflammatory tone. Critically, epithelial barriers regulate immune exposure to these signals, positioning barrier integrity as an upstream determinant of immunometabolic reprogramming. Altered epithelial metabolism compromises tight junction stability and metabolite flux, contributing to dysregulated immune activation and chronic inflammation. In this review, we synthesize current evidence supporting the concept that epithelial barriers act as metabolic gatekeepers of immunity, integrating microbial signals with host metabolic pathways to regulate immune function and disease susceptibility.
    Keywords:  epithelial barrier; immune function; inflammation; microbial metabolites; microbiota
    DOI:  https://doi.org/10.3389/fimmu.2026.1959305
  4. Biomark Res. 2026 Nov 06. pii: 159. [Epub ahead of print]14(1):
      Inflammatory bowel disease (IBD) is a chronic, immune-mediated disorder of the gastrointestinal tract and an escalating global public health challenge, particularly in newly industrializing regions. Its etiology and pathogenesis remain incompletely understood, although disrupted homeostasis between the intestinal microbiota and the mucosal immune system is implicated. Macrophages and T cells contribute to the balance between tissue injury and repair. Increasing evidence suggests that metabolic state and epigenetic programs interact to influence immune cell function. Under hypoxic and inflammatory stress, glucose, lipid, and amino acid metabolism can undergo remodeling, including shifts between glycolysis and oxidative phosphorylation, altered fatty-acid utilization, changes in tryptophan and methionine metabolism, and fluctuations in methyl-donor availability. Metabolic cues may influence chromatin regulation and immune signaling through acetylation, methylation, lactylation, palmitoylation, phosphorylation, and other modifications. These processes can affect effector programs, the T helper 17-regulatory T cell balance, macrophage inflammatory gene expression, inflammasome activation, and interleukin-10-related signaling, with potential implications for mucosal barrier repair and inflammatory amplification. However, the causal roles of these metabolic and epigenetic alterations in IBD remain to be clarified: they may contribute to disease initiation, arise as accompanying features of the disease state, or amplify inflammation once it is established. This review synthesizes current advances in metabolic reprogramming and epigenetic regulation in macrophages and T cells, examining immunometabolic nodes that link environmental stress to chromatin remodeling. We further summarize emerging therapeutic strategies targeting metabolic and epigenetic pathways, assess evidence from preclinical and clinical studies, and discuss interventions directed at immunometabolic checkpoints.
    Keywords:  Epigenetic regulation; Immunometabolism; Inflammatory bowel disease; Metabolic reprogramming
    DOI:  https://doi.org/10.1186/s40364-026-01037-4
  5. J Biomed Opt. 2026 Nov;31(11): 115002
       Significance: T cell activation and function are tightly linked to metabolic reprogramming, yet accessible, label-free methods to monitor these changes remain limited. Optical redox imaging (ORI) with two-photon microscopy has been utilized for studying metabolic functions and activation of immune cells, but this approach requires complex systems and is not as accessible and low-cost as single-photon wide-field fluorescence microscopy.
    Aim: We aim to develop and validate wide-field ORI for assessing metabolic states and heterogeneity in human T cells.
    Approach: A wide-field inverted fluorescence microscope was used to perform ORI in vitro to evaluate and differentiate between unstimulated T cells and natural killer (NK) cells to demonstrate the technical feasibility of a wide-field system for studying immune cells. To avoid misrepresentation of activated T cells, an ORI protocol was optimized for imaging T cells from human donors seeded in and adherent to noncoated glass-bottom dishes. Intrinsic fluorescence of reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) and oxidized flavoproteins (Fp) was measured to compute the optical redox ratio ( ORR= Fp/[NAD(P)H+Fp] ). Quiescent and anti-CD3/CD28/CD2-activated T cells were characterized and compared, along with their responses to mitochondrial modulators of oxidative phosphorylation (OXPHOS).
    Results: Wide-field ORI differentiated total, CD4+, and CD8+ T cells from NK cells based on Fp, NAD(P)H, and ORR indices. Activation significantly increased NAD(P)H levels and decreased ORR in total, CD4+, and CD8+ T cells, indicating a more reduced mitochondrial redox state. ORI distinguished quiescent from activated T cells and revealed differences in metabolic heterogeneity and responses to OXPHOS perturbations. ORR images and histogram analysis of ORR indicated the existence of redox subpopulations in T cell samples.
    Conclusions: Generating results consistent with ORI using two-photon microscopy, single-photon wide-field ORI provides a sensitive, low-cost, and nondestructive platform for characterizing immune cell metabolism and function. This approach with wide accessibility will broaden the applications of ORI for studying immune cell function and therapeutic responses.
    Keywords:  NAD(P)H (reduced nicotinamide adenine dinucleotide (phosphate)); NADH (reduced nicotinamide adenine dinucleotide); T cell activation; flavin adenine dinucleotide; metabolism; optical redox imaging
    DOI:  https://doi.org/10.1117/1.JBO.31.11.115002
  6. Cells. 2026 Oct 26. pii: 1949. [Epub ahead of print]15(21):
      Metabolic abnormalities in rheumatoid arthritis (RA) differ across cell populations and anatomical compartments. Glycolytic synovial fibroblasts coexist with blood T-cell populations showing impaired glycolytic induction or mitochondrial function, while macrophage metabolism can sustain inflammation or tissue protection. These differences complicate systemic metabolic inhibition. This narrative review integrates human RA studies, experimental arthritis and mechanistic work in other systems to identify dependencies that support defined pathogenic functions. We examine metabolite transport, nutrient adaptation and nutrient and energy sensing, distinguishing causal perturbation from descriptive signatures and preclinical hypotheses from clinical efficacy signals. Systemic cardiometabolic disease and nutritional interventions provide a clinical context for interpreting local metabolic findings. Small trials of repurposed drugs suggest possible benefit during treatment, but do not establish durable metabolic correction. We propose that a claim of reprogramming requires persistent functional change after drug removal, exclusion of residual exposure and selective cell loss, and preservation of immune regulation and host defence. These criteria could guide more selective metabolic interventions and their evaluation in patient tissue.
    Keywords:  immunometabolism; metabolic heterogeneity; metabolic reprogramming; rheumatoid arthritis; synovial fibroblasts
    DOI:  https://doi.org/10.3390/cells15211949
  7. Cell Oncol (Dordr). 2026 Aug 19. pii: 150. [Epub ahead of print]49(6):
       BACKGROUND: Tumor metabolic reprogramming shapes the tumor microenvironment (TME) and modulates anti-tumor immunity, yet the interplay between metabolic adaptation and immune regulation in intrahepatic cholangiocarcinoma (ICC) remains unclear. We investigated the role of the glucose transporter GLUT1 (SLC2A1) as a potential immunometabolic regulator in ICC.
    METHODS: We integrated bulk and single-cell transcriptomics with multi-omics profiling, and performed in vitro and in vivo functional validation. Pharmacologic inhibition was achieved using the selective GLUT1 inhibitor BAY-876. Single-cell analyses and tumor cell-macrophage co-culture assays were used to characterize immune composition and macrophage polarization. Mechanistic studies probed signaling pathways linking glucose transport to cytokine release and macrophage activation.
    RESULTS: GLUT1 expression was increased in malignant cholangiocytes and associated with worse prognosis. Single-cell data revealed stage-dependent GLUT1 dynamics, peaking at intermediate tumor states and declining during late-stage metabolic shifts toward lipid and MYC-driven programs. BAY-876 suppressed tumor cell proliferation and reduced tumor burden in preclinical models. High GLUT1 abundance correlated with an immune-suppressed TME reduced overall immune infiltration and predominance of M2-like macrophages, whereas GLUT1 inhibition increased tumor cell release of TNFα, activated NF-κB signaling in macrophages, and promoted M1-like polarization. Mechanistically, GLUT1 blockade activated p53 signaling and enhanced ADAM17 maturation, facilitating proteolytic release of TNFα and thereby engaging a p53/ADAM17/TNFα/NF-κB axis that links glucose transport to macrophage phenotype.
    CONCLUSIONS: These data nominate GLUT1 as an immunometabolic regulator in ICC and provide a rationale to evaluate GLUT1-directed strategies, alone or combined with immune-modulatory agents, to overcome metabolic heterogeneity and remodel the TME.
    Keywords:  ADAM17; BAY-876; GLUT1; Immunometabolism; Intrahepatic cholangiocarcinoma; Macrophage polarization
    DOI:  https://doi.org/10.1007/s13402-026-01275-6
  8. Cell Commun Signal. 2026 Aug 12. pii: 600. [Epub ahead of print]24(1):
       BACKGROUND: Neonatal sepsis remains a major cause of morbidity and mortality in preterm infants and is characterized by dysregulated inflammation and metabolic dysfunction. Excessive glycolysis has been linked to inflammatory injury during neonatal infection, but whether metabolic reprogramming can improve host defense and survival remains unclear. We investigated whether ketone-supported mitochondrial metabolism, together with anti-inflammatory signaling actions of beta-hydroxybutyrate (BHB), promotes disease tolerance during neonatal sepsis.
    METHODS: Using a preterm piglet model of Staphylococcus epidermidis bloodstream infection, we assessed the effects of glycolytic inhibition with 2-deoxyglucose and parenteral BHB supplementation on survival, acid-base balance, bacterial burden, systemic inflammation, plasma metabolome, and hepatic transcriptional responses. Mechanistic studies were performed in infected THP-1 macrophages, and human relevance was explored in a cohort of 538 children with plasma metabolomics and cytokine profiling. Animal data were analyzed using additive linear or linear mixed-effects models with estimated marginal means and Tukey adjustment for multiple comparisons; in vitro comparisons used paired t-tests or Wilcoxon signed-rank tests, as appropriate.
    RESULTS: Glycolytic inhibition protected infected piglets from lethal sepsis and was associated with reduced inflammatory responses and induction of mitochondrial and ketone-associated metabolic pathways. BHB supplementation prevented sepsis-related mortality, improved acid-base homeostasis, and promoted a disease-tolerant phenotype without reducing bacterial burden. Hepatic transcriptomics showed suppression of inflammatory pathways together with activation of mitochondrial and organic-acid metabolic programs. In infected THP-1 macrophages, BHB reduced pro-inflammatory cytokine expression, and this effect persisted despite blockade of ATP synthesis, supporting anti-inflammatory actions beyond metabolic modulation. In the pediatric cohort, higher circulating ketone levels were associated with higher IL-10 and lower interferon-gamma concentrations, consistent with an anti-inflammatory effect of BHB in humans.
    CONCLUSIONS: Ketone supplementation promotes disease tolerance and survival in experimental neonatal sepsis through combined metabolic and anti-inflammatory effects, with data supporting a signaling-active role for BHB in shaping inflammatory responses. These findings identify BHB as a candidate host-directed intervention for neonatal sepsis and support further translational evaluation in preterm infants.
    DOI:  https://doi.org/10.1186/s12964-026-03136-z
  9. Mol Neurobiol. 2026 Nov 13. pii: 1033. [Epub ahead of print]63(1):
      Diabetes-associated cognitive dysfunction (DACD) is a significant complication with few effective treatments and unclear underlying mechanism. The aim of this study was to investigate how hyperglycemia disrupts adult hippocampal neurogenesis (AHN) through metabolic-immune interactions, seeking to identify potential treatment targets for DACD. DACD models were developed using db/db mice or streptozotocin-induced mice, and their cognitive function was assessed through behavioral tests. Next, we integrated multi-omics analyses (transcriptomic, single-cell, and lactylome profiling) with metabolic studies in BV2 cells exposed to diabetic conditions. Pharmacological modulators (3-BP, C646, TSA) were used to clarify the underlying mechanisms. The mice with DACD demonstrated cognitive deficits, impaired AHN, and activation of hippocampal microglia. Transcriptomic analysis revealed glycolysis as the primary dysregulated pathway. Mechanistically, hyperglycemia/AGEs induced glycolytic reprogramming and increased lactate levels, which promoted HIF-1α lactylation at lysine residues-a modification catalyzed by p300 and opposed by histone deacetylases. This posttranslational modification was associated with HIF-1α stabilisation and with enhanced transcriptional occupancy at the HK2 promoter. This established a self-amplifying feedback loop, perpetuating microglial activation and disrupting the blood-brain barrier via CXCL10 secretion, which led to CD8+ T-cell infiltration. Systemic administration of the glycolytic inhibitor 3-BP disrupted the pathogenic circuit, thereby normalizing metabolism, attenuating neuroinflammation, and restoring cognitive function. HIF-1α lactylation is associated with HIF-1α stabilisation, acting as a potential metabolic-epigenetic mechanism that links glycolytic flux to sustained microglial activation, neuroinflammation and impaired AHN in DACD. Pharmacological inhibition of this axis attenuated neuroinflammation and improved cognitive outcomes in our model, suggesting a candidate therapeutic strategy for DACD.
    Keywords:  Diabetic-associated cognitive dysfunction; Glycolysis; Hexokinase; Hypoxia-inducible factor 1-alpha; Lactylation
    DOI:  https://doi.org/10.1007/s12035-026-06348-z
  10. Immunity. 2026 Nov 10. pii: S1074-7613(26)00436-X. [Epub ahead of print]59(11): 2879-2881
      Metabolites can regulate T cell gene expression and effector function, but how changes in mitochondrial ATP production influence chromatin remodeling remains unclear. In a recent issue of Cell, Ng et al. demonstrate that D-α-hydroxybutyrate (DAHB) increases oxidative phosphorylation and phosphocreatine production, promoting chromatin accessibility and CD8+ T cell effector function to limit tumor growth.
    DOI:  https://doi.org/10.1016/j.immuni.2026.10.010
  11. MedComm (2020). 2026 Nov;7(11): e71127
      Mitochondria are key regulators of cellular metabolism and innate immunity, and diverse viruses manipulate these organelles during infection. Viral proteins interact with respiratory chain complexes to regulate oxidative phosphorylation (OXPHOS) and reprogram host bioenergetics, thereby influencing viral replication or host antiviral responses. OXPHOS can be directly altered by viral factors or indirectly regulated through virus-induced changes in host metabolism and signaling. Beyond OXPHOS, viral infection perturbs mitochondrial metabolism, dynamics, calcium homeostasis, membrane potential, redox regulation, and apoptosis, linking mitochondrial alterations to viral replication and virus-associated cellular responses. This review focuses on how viruses regulate mitochondrial function, with particular emphasis on OXPHOS while addressing other mitochondrial processes in viral infection. We further distinguish mitochondrial alterations functionally linked to viral infection outcomes from those observed during infection without direct evidence of their effects on viral infection outcomes. Mitochondrial pathways have dual functions during infection, as viruses can hijack these pathways to promote infection, whereas hosts can utilize them to support antiviral responses. By integrating these mechanistic and experimental findings, this review highlights virus-specific patterns of mitochondrial regulation and their functional significance during infection. A mechanistic understanding of these mitochondrial responses provides a basis for identifying mitochondrial pathways as potential antiviral targets.
    Keywords:  innate immunity; metabolic reprogramming; mitochondria; oxidative phosphorylation (OXPHOS); viral replication
    DOI:  https://doi.org/10.1002/mco2.71127
  12. bioRxiv. 2026 Oct 23. pii: 2026.10.22.760948. [Epub ahead of print]
      Metabolite-based polymer nanoparticles can transform endogenous immunometabolites into intrinsically bioactive materials, yet most platforms have focused on itaconate or soluble metabolite analogs. Mesaconate is a downstream itaconate-derived immunometabolite with distinct metabolic activity, but its potential as an engineerable material building block remains largely unexplored. Here, mesaconic acid was used as a monomer to construct a degradable, cargo-free polyester nanoparticle platform. Poly(itaconate-co-decanediol) (pITA) and poly(mesaconate-co-decanediol) (pMSA) were synthesized using 1,10-decanediol and formulated into nanoparticles. Varying pMSA synthesis conditions generated distinct molecular-weight development, thermal organization, and degradation-associated behavior. Despite comparable particle size, surface charge, and morphology, pITA- and pMSA-derived nanoparticles produced activation-state-dependent macrophage immunomodulation. Under inflammatory stimulation, both nanoparticles modulated activation-associated surface molecules, whereas their transcriptomic responses diverged markedly. pITA-NPs preferentially engaged redox-, metabolic-, and cellular stress-associated programs, while pMSA-NPs exhibited a distinct lysosome-associated, inflammatory, and remodeling transcriptional profile and remained distinguishable from soluble 4-octyl itaconate. In LPS-induced endotoxemia, pMSA-NP treatment broadly modulated systemic cytokine responses, including a pronounced reduction in circulating IL-6, and improved seven-day survival relative to vehicle control. Together, these findings establish mesaconate as a synthesis-tunable polymeric immunometabolite and highlight metabolite-isomer identity and nanoparticle material state as complementary design parameters for cargo-free immunometabolic biomaterials.
    DOI:  https://doi.org/10.64898/2026.10.22.760948
  13. J Inflamm Res. 2026 ;19 651180
      Intervertebral disc degeneration (IVDD) is accompanied by extracellular-matrix disruption, metabolic stress and immune-cell infiltration, but how metabolites mediate communication between disc cells and macrophages remains incompletely defined. This narrative review examines lactate, succinate and kynurenine as candidate signalling metabolites at the macrophage-disc cell interface and proposes an integrative metabolite-centred framework. Evidence is strongest for lactate, which is supported by IVDD-specific studies linking glycolytic adaptation and impaired clearance to acidosis, MCT-dependent metabolic coupling, ASIC/NLRP3 activation, lactylation, cellular senescence and matrix catabolism. Evidence for succinate is more limited: IVDD-specific studies support SIRT5-AIFM1-dependent succinylation and mitochondrial dysfunction, whereas succinate accumulation and SUCNR1-mediated macrophage signalling in human degenerative discs remain unverified. The kynurenine-AhR axis is primarily hypothesis-generating; emerging IVDD-related observations implicate AhR and tryptophan-pathway changes, but a causal kynurenine-AhR macrophage-disc pathway has not been established. We propose that degenerating disc cells may reprogramme the local metabolic microenvironment, thereby altering macrophage functional states and creating a self-amplifying immunometabolic loop that feeds back on disc-cell injury and extracellular-matrix degradation. Future studies should combine spatial immunometabolomics in human tissue with cell-specific and causal intervention experiments to distinguish established mechanisms from context-dependent or extrapolated pathways and to evaluate potential microenvironment-directed therapeutic targets.
    Keywords:  immunometabolism; intervertebral disc degeneration; kynurenine; lactate; macrophages; succinate
    DOI:  https://doi.org/10.2147/JIR.S651180
  14. Immunology. 2026 Nov 09.
      Tolerogenic dendritic cells (tolDCs) maintain immune tolerance by suppressing effector T cells while inducing regulatory T cells (Treg). Importantly, tolDCs play critical roles in suppressing pathogenic activation and maintaining homeostasis in immune-mediated diseases. This highlights the need to define the molecular mechanisms sustaining their stable tolerogenic identity. Although tolDCs are typically characterized by downregulated co-stimulatory molecules and upregulated anti-inflammatory cytokines, this phenotype alone fails to fully define their tolerogenic nature. Emerging evidence links signalling pathways, metabolic adaptation and epigenetic regulation in shaping the tolDC landscape. While acting through different initial receptors, distinct tolerogenic stimuli─such as 1,25-dihydroxyvitamin D3 (VitD3), dexamethasone (Dex) and rapamycin─converge on core signalling regulators, including mammalian target of rapamycin (mTOR), AMP-activated protein kinase (AMPK) and signal transducer and activator of transcription 3 (STAT3). These central checkpoints directly drive metabolic reprogramming, encompassing oxidative phosphorylation (OXPHOS), fatty acid oxidation (FAO), tricarboxylic acid (TCA) cycle and glycolysis. These metabolic adaptations subsequently reshape chromatin organization through metabolite-dependent regulation of DNA methylation and histone modification. Accordingly, metabolite-mediated epigenetic remodelling effectively locks these pathways to stabilize the tolerogenic state, fixing the enzymatic and secretome programmes required for robust Treg polarization despite phenotypic plasticity. This review discusses the signalling pathways driving tolerogenic metabolic adaptation, the mechanisms linking metabolism to epigenetic regulation and the implications of this signalling-metabolism-epigenetic axis for tolDC identity, immune regulation and therapeutic applications in immune-mediated and inflammatory diseases, as well as in transplantation.
    Keywords:  epigenetic regulation; immune tolerance; immunometabolism; signalling pathways; tolerogenic dendritic cells
    DOI:  https://doi.org/10.1111/imm.70226
  15. Sci Signal. 2026 Nov 10. 19(963): eaef6579
      Macrophages undergo metabolic reprogramming during inflammatory responses to microbial infection, in part because of activation of the transcription factor HIF-1α (hypoxia-inducible factor 1α). Here, we identified regulators of HIF-1α-dependent gene expression during immune activation induced by lipopolysaccharide (LPS) and during the hypoxic response using genome-wide CRISPR screens in cultured mouse macrophages. The small neutral amino acid transporter SNAT2 (encoded by Slc38a2) was a key inhibitor of HIF-1α activation and metabolic reprogramming in cultured and bone marrow-derived mouse macrophages in response to LPS but not to hypoxia. Inflammatory stimulation increased SNAT2 protein abundance and dynamically expanded intracellular amino acid pools in a largely SNAT2-dependent manner. Consistent with the role of intracellular amino acids as osmolytes, SNAT2 deficiency resulted in osmotic imbalance and aberrant activation of NFAT5, a central transcriptional regulator of osmotic stress responses. In turn, NFAT5 promoted nitric oxide- and HIF-1α-dependent metabolic reprogramming and augmented NLRP3 inflammasome activation under hyperosmotic conditions. Supplementation with organic osmolytes mitigated both the excessive metabolic reprogramming and hyperosmotic inflammasome activation in SNAT2-deficient macrophages. Consistent with the heightened inflammatory phenotype in vitro, myeloid-specific deletion of SNAT2 reduced bacterial burden in mice infected with Listeria monocytogenes. Together, these findings identify SNAT2 as a negative feedback regulator that restrains macrophage metabolic reprogramming and inflammatory activation by maintaining amino acid availability that supports osmotic homeostasis.
    DOI:  https://doi.org/10.1126/scisignal.aef6579
  16. Front Immunol. 2026 ;17 1947853
      Glioblastoma (GBM) is an aggressive primary brain tumor whose progression and resistance to therapy are driven not only by malignant cells but also by extensive metabolic and immunological remodeling of the tumor microenvironment (TME). Among the most abundant immune populations within the GBM TME are tumor-associated macrophages (TAMs), including resident microglia and infiltrating monocyte-derived macrophages. Under physiological conditions, microglia preserve central nervous system (CNS) homeostasis through immune surveillance, phagocytosis, synaptic remodeling, and metabolic regulation. However, exposure to tumor-derived signals, hypoxia, and nutrient deprivation reprograms these cells toward predominantly immunosuppressive phenotypes that promote tumor growth, angiogenesis, immune evasion, and therapeutic resistance. Emerging evidence demonstrates that TAMs engage in extensive bidirectional communication with B cells, further shaping the immunosuppressive landscape of GBM. Macrophages regulate B-cell activation, survival, differentiation, and antigen presentation through cytokines, chemokines, growth factors, and direct cell-cell interactions, while B cells influence macrophage polarization through antibody production and inflammatory signaling. Simultaneously, metabolic competition within the TME, characterized by glucose depletion, lactate accumulation, and hypoxia, impairs B-cell effector functions, diminishes antigen presentation and humoral immunity, and promotes the development of regulatory B cells (Bregs), thereby reinforcing immune suppression and facilitating tumor progression. This review summarizes the physiological functions of microglia, the metabolic and functional reprogramming of tumor-associated myeloid populations in GBM, and the emerging evidence surrounding TAM-B-cell interactions. By integrating findings from GBM with mechanistic insights from other tumor and disease contexts, we examine how metabolic constraints within the TME could potentially influence macrophage-B-cell crosstalk. We propose this relationship as a novel and testable framework for understanding immune regulation in GBM, while distinguishing established GBM-specific mechanisms from pathways supported primarily by evidence in other disease settings. Finally, we discuss how macrophage immunometabolism and its potential intersection with B-cell function may represent areas for future investigation and therapeutic exploration in GBM.
    Keywords:  B cell; glioblastoma; immunometabolism; macrophages; microglia; tumor microenvironment
    DOI:  https://doi.org/10.3389/fimmu.2026.1947853
  17. Front Physiol. 2026 ;17 1883296
       Background: Doxorubicin-induced cardiotoxicity remains a major clinical challenge. The intricate immunomodulatory pathways responsible for cardiac damage remain incompletely defined. Cardiac CCR2+ MHC IIhigh macrophages have emerged as a critical subset contributing to inflammatory cardiovascular injury. However, the precise exacerbating role and mechanisms by which these macrophages contribute to doxorubicin-induced myocardial injury remain elusive. Metabolic reprogramming significantly influences the transition of macrophages to an inflammatory phenotype, and pyruvate kinase M2 (PKM2), a key rate-limiting enzyme of glucose metabolism, may be a possible regulatory node and a promising therapeutic target for intervention.
    Methods: Doxorubicin-induced cardiotoxicity model was established in C57BL6/J mice. This model was utilized to assess the dynamic change relationship between cardiac function, cardiac CCR2+ MHC IIhigh macrophages, and myocardial injury remodeling. Also, the crosstalk between macrophage phenotypic switching and cardiomyocyte damage was explored in vitro. We further investigated the role of PKM2 in CCR2+ macrophage metabolic reprogramming and the therapeutic potential of using Shikonin to inhibit PKM2 to ameliorate cardiac injury. Moreover, peripheral blood cells from patients receiving Doxorubicin chemotherapy were used to verify the changes in PKM2 in macrophages, which revealed the role of metabolic reprogramming in pro-inflammatory macrophages.
    Results: CCR2+ MHC IIhigh macrophages may play a crucial role in exacerbating sustained cardiotoxicity caused by Doxorubicin. In vitro studies have shown that PKM2 facilitates the transition of macrophages into a pro-inflammatory CCR2+ phenotype. The phosphorylation of PKM2 mechanistically contributes to the metabolic reprogramming of these pro-inflammatory CCR2+ macrophages. In vivo and in vitro experiments have demonstrated that pharmacological inhibition of PKM2 with Shikonin mitigates doxorubicin-induced cardiotoxicity.
    Conclusion: Our results reveal a pivotal metabolic regulator of cardiac CCR2+ MHC IIhigh macrophages through metabolic reprogramming. Targeting PKM2 could offer a novel approach for mitigating Doxorubicin-induced myocardial inflammatory damage. Exploring the impact of CCR2+ macrophages on exacerbating myocardial injury sheds new light on the interplay between aberrant immune response of macrophage and Doxorubicin-induced myocarditis.
    Keywords:  CCR2+ MHC IIhigh macrophage; Doxorubicin; Shikonin; cardiotoxicity; metabolic reprogramming
    DOI:  https://doi.org/10.3389/fphys.2026.1883296
  18. Adv Sci (Weinh). 2026 Nov 11. pii: e78795. [Epub ahead of print]
      Chronic obstructive pulmonary disease (COPD) is a devastating condition characterized by airflow limitation, inflammation, and structural lung damage. Metabolic dysregulation is recognized as a critical feature, but the key metabolic drivers remain unclear. This study identifies transaldolase1 (TALDO1) as a previously unrecognized metabolic regulator in cigarette smoke (CS)-induced COPD pathogenesis. TALDO1 is markedly upregulated in airway epithelial cells by CS exposure. Elevated TALDO1 promotes mitochondrial dysfunction, whereas its genetic knockdown attenuates CS-induced lung function decline and pulmonary inflammation. Mechanistically, TALDO1 activation redirects tryptophan metabolism toward the kynurenine pathway, leading to L-kynurenine accumulation. Genetic or pharmacological inhibition of this pathway significantly alleviates mitochondrial damage, while L-kynurenine supplementation exacerbates injury. Treatment with the IDO inhibitor Epacadostat ameliorates CS-induced lung impairment and inflammation in vivo. These findings define a TALDO1-kynurenine-mitochondrial injury axis linking airway epithelial metabolic reprogramming to COPD, providing translational evidence for targeting this pathway as a therapeutic strategy.
    Keywords:  L‐kynurenine; TALDO1; chronic obstructive pulmonary disease; mitochondrial injury
    DOI:  https://doi.org/10.1002/advs.78795
  19. Cell Rep. 2026 Nov 10. pii: S2211-1247(26)01392-6. [Epub ahead of print]45(11): 118313
      Nutrient metabolism influences HIV-1 replication, antiviral immunity, and chronic inflammation, yet remains difficult to leverage therapeutically. Using a non-human primate model of HIV-1, we modulated metabolism through caloric restriction (CR). Four months of 30% CR was safe and induced metabolic reprogramming in rhesus macaques. Compared with ad libitum-fed animals, CR reduced gut mucosal CCR5+ CD4+ T cell frequencies. Following SIV infection, CR reduced acute viremia, dampened type I interferon signaling, and enhanced CD8+ T cell cycling in lymphoid tissues. CR-associated protection coincided with glycolytic upregulation, supporting an early reduction in viremia that waned over time. Following antiretroviral therapy, CR limited gastrointestinal immune activation, improved tricarboxylic acid cycle flux, and reduced plasma sCD14 and TNF-related molecules. Blood SIV DNA remained unchanged, suggesting GI inflammation can be decoupled from viral persistence. These findings demonstrate that dietary intervention can limit lentiviral pathology while revealing the temporally constrained nature of glycolysis in supporting antiviral responses.
    Keywords:  CP: immunology; CP: metabolism; HIV; SIV; T cells; TCA cycle; caloric restriction; glycolysis; gut health; metabolism
    DOI:  https://doi.org/10.1016/j.celrep.2026.118313
  20. Clin Epigenetics. 2026 Aug 12. pii: 207. [Epub ahead of print]18(1):
      Histone lactylation, particularly H3K18 lactylation (H3K18la), has emerged as a lactate-derived epigenetic modification that links metabolic reprogramming to sustained chromatin states. Here, we advance a hypothesis that the lactate-p300-H3K18la axis functions as an epigenetic memory code, converting transient glycolytic signals into persistent transcriptional responsiveness in innate immune cells-a mechanism we term "context-dependent lactylation memory." We integrate evidence from three converging domains: the persistence of lactylation at trained immune loci, the requirement of H3K18la for trained immunity demonstrated in recent BCG vaccination studies, and the hypoxic, glycolytic microenvironment of the atherosclerotic plaque. We propose that cardiovascular risk factors stabilize HIF-1α, which drives glycolytic reprogramming and sustained lactate production. Lactate-derived lactyl-CoA then serves as a substrate for p300/CBP-mediated H3K18la deposition at immune gene regulatory elements, creating a poised chromatin state that sustains innate immune hyperresponsiveness. This cascade provides a mechanistic explanation for residual inflammatory risk, the observation that elevated cardiovascular events persist despite optimal lipid-lowering therapy. The framework is constrained by the context-dependent duality of lactylation, whereby cell type, lysine site, and metabolic flux direction jointly determine whether the modification drives pro-inflammatory or reparative outcomes. We delineate testable predictions that define a roadmap for empirical validation or refutation of the lactate-lactylation memory hypothesis in human CHD.
    Keywords:  Atherosclerosis; Coronary heart disease; H3K18 lactylation; HIF-1alpha; Histone lactylation; Immunometabolism; Residual inflammatory risk; Trained immunity
    DOI:  https://doi.org/10.1186/s13148-026-02224-8
  21. Immunohorizons. 2026 Nov 05. pii: vlag059. [Epub ahead of print]10(11):
      Malaria pathogenesis is driven by dynamic host-parasite interactions that integrate immune, metabolic, and iron-regulatory networks; however, the temporal coordination of these host responses during blood-stage infection remains incompletely defined. Using the rodent model of Plasmodium yoelii infection, which recapitulates key features of human malaria including anemia and systemic inflammation, we investigated the kinetic relationships between parasite burden and host immunometabolic and iron-regulatory responses. To define the host response, we performed a longitudinal study of P. yoelii infection in C57BL/6J mice. Progressive parasitemia was associated with coordinated development of anemia, systemic inflammatory responses, and dysregulation of metabolic and iron-related pathways. Infection induced a robust hepatic immunometabolic response characterized by mitochondrial remodeling, oxidative stress, disruption of bile acid homeostasis, and iron-regulatory responses. Interestingly, mitochondrial copy number was progressively reduced during infection, indicating impaired mitochondrial renewal during disease progression. Progressive mitochondrial remodeling was further confirmed by Western blot analysis of key regulators of mitochondrial dynamics, including UCP1 and UCP2 and OPA1. Concomitantly, iron homeostasis was dynamically reprogrammed, as evidenced by temporal modulation of hepatic hepcidin, ferroportin, transferrin, and erythrocyte ferroportin expression. Collectively, these data define a coordinated immunometabolic and iron-regulatory program during blood-stage malaria infection and reveal temporal host responses that track with disease progression. This study provides a framework for understanding how systemic immune activation integrates with metabolic and iron-handling pathways to shape malaria pathogenesis.
    Keywords:  RBC; bile acid metabolism; ferroportin; hepcidin; mitochondrial function
    DOI:  https://doi.org/10.1093/immhor/vlag059
  22. Immunology. 2026 Nov 11.
      Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality worldwide, with its progression and therapeutic resistance increasingly recognized as consequences of complex metabolic and immune interactions within the tumour microenvironment (TME). Recent advances in single-cell and spatial multi-omics technologies have enabled detailed characterisation of metabolic heterogeneity among TME components, uncovering how distinct metabolic states influence immune function and therapeutic responses. In this review, we summarize recent advances in our understanding of metabolic regulation in the CRC microenvironment, with a particular focus on how distinct immune cell populations contribute to tumour progression and immune suppression through diverse metabolic pathways. We discuss key metabolite-driven signalling networks involving lactate, short-chain fatty acids, bile acids, and amino acid derivatives, and examine how these pathways influence immune cell function and tumour-immune interactions. Furthermore, we highlight emerging therapeutic approaches targeting the metabolic-immune axis, including glutaminase inhibitors, CD36 antagonists, and combination regimens integrating metabolic intervention with immune checkpoint inhibitors. By integrating recent mechanistic discoveries with therapeutic perspectives, this review provides an updated overview of the metabolic-immune landscape in CRC and discusses potential strategies to exploit metabolic vulnerabilities for improving immunotherapy efficacy and overcoming treatment resistance.
    Keywords:  colorectal cancer; immunometabolism; metabolic reprogramming; tumour microenvironment
    DOI:  https://doi.org/10.1111/imm.70230
  23. Immunology. 2026 Nov 10.
      Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand that has been implicated in inflammatory responses, but its direct role in priming macrophage pyroptosis remains poorly understood. Here, we demonstrate that AREG primes bone marrow-derived macrophages (BMDMs) for ATP-induced pyroptosis through an autocrine Ccl2-dependent positive-feedback loop that requires sustained NF-κB activation. RNA-sequencing and functional clustering analyses revealed that AREG and LPS induce both convergent metabolic reprogramming and divergent transcriptional programs in macrophages. Notably, the chemokine signalling pathway was uniquely enriched in AREG-treated cells, with marked upregulation of Ccl2, Cxcl1, Cxcl3 and Cxcl16. Mechanistically, AREG induced Ccl2 secretion in an EGFR-dependent manner. Pharmacological inhibition (mNOX-E36) or antibody-mediated neutralisation of Ccl2 dose-dependently suppressed Caspase1/GSDMD cleavage and IL-1β/IL-18 release, and attenuated NF-κB p65 phosphorylation and IκBα degradation during AREG plus ATP stimulation. Consistently, siRNA-mediated Ccl2 knockdown phenocopied these effects, confirming that autocrine Ccl2 signalling sustains NF-κB activation to drive AREG-primed pyroptosis. Collectively, these findings identify a previously unrecognised AREG/EGFR/Ccl2/NF-κB axis that primes macrophages for pyroptosis, highlighting Ccl2 as a potential therapeutic target in sepsis and other inflammatory diseases driven by this amplification loop.
    Keywords:  AREG; Ccl2; Pyroptosis; inflammation; macrophage
    DOI:  https://doi.org/10.1111/imm.70224
  24. bioRxiv. 2026 Oct 21. pii: 2026.10.15.759372. [Epub ahead of print]
      Despite its promise in treating B cell malignancies, chimeric antigen receptor (CAR) T cell therapy remains limited by resistance mechanisms that impair CAR T cell stemness, persistence, and effector function. Here, we identified PRDM1 , which encodes the transcriptional repressor, BLIMP-1, as a crucial regulator of CAR T cell terminal differentiation and exhaustion. PRDM1 was highly enriched in exhausted-like tumor-infiltrating CAR T cells from lymphoma patients and in pre-infusion products from clinical non-responders. These findings link increased PRDM1 expression to CAR T cell dysfunction and poor clinical outcomes. Genetic deletion of PRDM1 significantly promoted CAR T cell proliferative capacity, memory differentiation and antitumor efficacy in both hematologic and solid tumor models. Mechanistically, PRDM1 deletion increased the activity of PGC1α, a transcriptional coactivator central to mitochondrial biogenesis and antioxidant capacity, thereby improving mitochondrial function, oxidative stress resistance, and metabolic reserve. Depletion of PGC1α attenuated the improved efficacy of PRDM1 -deficient CAR T cells, indicating an essential role for this pathway downstream of PRDM1 loss. Pharmacologic activation of the PPAR-PGC1α program with a clinically approved agonist, bezafibrate, enhanced CAR T cell antitumor activity without direct tumoricidal effects. Notably, transient exposure to bezafibrate during CAR T cell manufacturing was sufficient to confer durable treatment benefits. Together, our study defines a PRDM1 - PGC1Α axis that controls CAR T cell differentiation, mitochondrial fitness and therapeutic response, which provides a mechanistic and translational framework for advancing CAR T cell therapy across distinct tumor contexts.
    DOI:  https://doi.org/10.64898/2026.10.15.759372
  25. Cell Host Microbe. 2026 Nov 11. pii: S1931-3128(26)00441-5. [Epub ahead of print]34(11): 2081-2083
      Obesity and metabolic disorders are linked to the microbiome, but the underlying pathways remain poorly defined. In this issue of Cell Host & Microbe, Tan et al. identify a Clostridium immunis-derived exopolysaccharide that reduces interleukin-22 signaling to reshape visceral adipose immunometabolism, and their findings link microbial chemistry to host energy balance.
    DOI:  https://doi.org/10.1016/j.chom.2026.10.007
  26. Biochem Pharmacol. 2026 Nov 07. pii: S0006-2952(26)00943-3. [Epub ahead of print]254(Pt 4): 118600
      Atherosclerosis is driven by dyslipidemia and chronic inflammation. GPR146 has emerged as a regulator of cholesterol metabolism; however, whether GPR146 links lipid metabolism with macrophage inflammation during atherosclerosis remains unclear. Apolipoprotein E-deficient (ApoE-/-) mice were fed a high-fat diet for 12 weeks, followed by 4 weeks of intervention with adeno-associated virus (AAV)-mediated hepatic GPR146 knockdown or rosuvastatin treatment. Atherosclerotic lesions and plaque composition were assessed using Oil Red O staining and immunofluorescence. Lipid profiles, oxidized low-density lipoprotein (ox-LDL), and inflammatory markers were evaluated using enzymatic assays, ELISA, and qPCR, respectively. In ox-LDL-stimulated THP-1-derived macrophages, GPR146 was silenced to examine lipid accumulation, inflammatory responses, transcriptomic alterations, and the potential involvement of the JAK-STAT signaling pathway. GPR146 expression increased in atherosclerotic lesions, particularly in macrophage-rich regions. Hepatic GPR146 knockdown reduced atherosclerotic lesion burden, circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, ox-LDL accumulation, and inflammatory activation within plaques. In macrophages, GPR146 silencing suppressed ox-LDL-induced lipid accumulation, accompanied by reduced CD36 expression and decreased foam cell formation. GPR146 silencing also attenuated pro-inflammatory macrophage activation, as evidenced by reduced expression of inflammatory mediators. Transcriptomic analysis implicated JAK-STAT signaling, with reduced JAK2 and STAT3 expression following GPR146 silencing. Pharmacological inhibition of the JAK-STAT signaling partially recapitulated the anti-inflammatory effects associated with GPR146 knockdown. Together, these findings suggest that GPR146 contributes to lipid metabolic regulation and macrophage inflammatory responses during atherosclerosis and may represent a therapeutic target warranting further investigation.
    Keywords:  Atherosclerosis; GPR146; Immunometabolism; Lipid metabolism; Macrophage inflammation
    DOI:  https://doi.org/10.1016/j.bcp.2026.118600
  27. Cancer Metastasis Rev. 2026 Nov 07. pii: 85. [Epub ahead of print]45(4):
      Nicotinamide adenine dinucleotide (NAD+) functions in cancer as a compartmentalized signaling currency, coupling tumor cell fitness to immune competence within the tumor microenvironment (TME). In malignant cells, NAD+ sustains redox balance, poly(ADP-ribose) polymerase (PARP)-dependent DNA repair, sirtuin-mediated chromatin remodeling, and metabolic stress adaptation. In immune effector cells, the same metabolite governs mitochondrial integrity, effector persistence, and resistance to exhaustion. This duality is the basis of the explanation advanced here for why first-generation inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting salvage pathway enzyme, failed clinically when deployed as cytotoxic monotherapies without an immunometabolic rationale. This review synthesizes the field around a central premise: NAD+ operates as a context-dependent metabolic immune checkpoint whose therapeutic value depends on where in the tumor immune ecosystem the pathway is perturbed and whether checkpoint blockade is deployed concurrently. The therapeutic landscape is reorganized around five pharmacological classes, which differ in how far each has been tested: (i) NAMPT catalytic inhibitors, evaluated clinically and withdrawn; (ii) bifunctional NAMPT/programmed death-ligand (PD-L1) compounds and proteolysis-targeting chimera (PROTAC)-mediated NAMPT degradation, both preclinical; (iii) NAD+ precursor-based immunorestorative strategies, including ex vivo rescue of age-associated chimeric antigen receptor T (CAR-T) cell dysfunction through NMN/CD38 inhibitor combinations; (iv) adenosinergic axis targeting, in which anti-CD38 and anti-CD73 agents are approved or in trials while the proposed triple-blockade of CD38, CD73, and PD-1/PD-L1 remains untested; and (v) combinations with PARP and indoleamine 2,3-dioxygenase (IDO) inhibitors, which rest on mechanistic rationale. A tripartite pharmacological taxonomy distinguishes intracellular (iNAMPT), extracellular (eNAMPT), and vesicle-associated (vNAMPT) NAMPT as discrete drug targets. The analyses examines how TME acidification, precursor competition, and extracellular NAD+ catabolism through the CD38-CD203a-CD73 noncanonical adenosine axis reshape immune fitness, and why biomarker-guided separation of tumor-directed NAD+ depletion from immune-directed NAD+ restoration is required for rational clinical translation. Throughout, findings that are experimentally established are separated from those that remain contested or hypothetical, and the criteria under which the checkpoint designation is analytically useful, together with the conditions under which it is not, are stated explicitly.
    Keywords:  CD38–adenosine axis; Immune checkpoint resistance; NAD+ metabolism; NAMPT; Tumor immunometabolism
    DOI:  https://doi.org/10.1007/s10555-026-10393-4
  28. J Neuroinflammation. 2026 Aug 15. pii: 366. [Epub ahead of print]23(1):
      Monocytes and monocyte-derived macrophages are increasingly recognized as key contributors to the initiation and progression of inflammatory conditions, in part through metabolic reprogramming that drives pathogenic inflammatory phenotypes. However, the upstream mechanisms that coordinate these early metabolic transitions in multiple sclerosis (MS) remain largely undefined. We previously identified extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), a chaperone of monocarboxylate transporter 4 (MCT4), as a regulator of lactate efflux and glycolysis-dependent activation in murine macrophages. Here, we investigate the role of EMMPRIN in circulating CCR2+ monocytes during experimental autoimmune encephalomyelitis (EAE), a mouse model for MS. Using the newly generated CCR2CreERT2:EMMPRINfl/fl (CCR2:EMMP-/-) mice, we demonstrate that presymptomatic deletion of EMMPRIN prevents or significantly attenuates clinical disability and is associated with a marked reduction in CNS infiltration by CD45+ leukocytes, including macrophages and T cells. Single cell RNA-sequencing of blood monocytes during pre-onset EAE, combined with proteomic profiling of bone marrow-derived macrophages from CCR2:EMMP-/- mice, reveals coordinated metabolic reprogramming characterized by reduced glycolytic activity, enhanced mitochondrial electron transport, and increased fatty acid oxidation. These data identify EMMPRIN-mediated lactate export as a pivotal regulator of immunometabolic programming in monocytes and monocyte-derived macrophages and implicate this pathway as an upstream driver of early neuroinflammatory pathology in MS. Targeting this pathway during presymptomatic phases may therefore represent a promising strategy to prevent disease progression by modulating early inflammatory metabolism.
    DOI:  https://doi.org/10.1186/s12974-026-03991-0
  29. CNS Neurosci Ther. 2026 Nov;pii: e71268. [Epub ahead of print]32(11):
       BACKGROUND: Sepsis-associated encephalopathy (SAE) is a frequent neurological complication of sepsis characterized by acute neurobehavioral abnormalities and persistent cognitive impairment. Although 4-octyl itaconate (4-OI) possesses potent immunomodulatory properties, its neuroprotective effects and underlying mechanisms in SAE remain unclear.
    METHODS: Sepsis was induced by cecal ligation and puncture (CLP), and mice were treated with 4-OI. Behavioral tests were used to assess anxiety-like behavior and cognitive function. Transcriptomic and single-cell RNA-seq analyses were performed to characterize efferocytosis-related changes in the septic hippocampus. Western blot, immunofluorescence, flow cytometry, experiments using primary neutrophils and microglia, pharmacological interventions, and Padi4-/- mice were used to investigate NET formation and microglial efferocytosis.
    RESULTS: 4-OI improved neurobehavioral and cognitive outcomes, reduced hippocampal injury, blood-brain barrier disruption, and neuroinflammation, and suppressed NET accumulation in the septic hippocampus and LPS-stimulated neutrophils. NRF2 inhibition weakened the effects of 4-OI on neutrophil PD-L1 expression and NET formation, whereas PD-L1 neutralization reduced NET formation. Transcriptomic analyses identified microglia/myeloid-associated efferocytosis programs. NETs impaired microglial efferocytosis, while DNase I treatment or PAD4 deficiency preserved apoptotic cell clearance.
    CONCLUSIONS: 4-OI protects against septic brain injury and cognitive dysfunction by activating NRF2, suppressing PD-L1-mediated NET formation, and mitigating NET-associated impairment of microglial efferocytosis.
    Keywords:  4‐octyl itaconate; microglial efferocytosis; neutrophil extracellular traps; sepsis‐associated encephalopathy
    DOI:  https://doi.org/10.1002/cns.71268
  30. iScience. 2026 Nov 20. 29(11): 118108
      Activated fibroblast-like synoviocytes (FLS) drive rheumatoid arthritis (RA) progression by recruiting immune cells. Metabolic reprogramming, marked by enhanced glycolysis and lactate accumulation, contributes to RA pathogenesis. Here, an analysis of a public metabolomics dataset identified elevated plasma lactate in patients with RA. Histone lactylation was increased in synovial FLS from patients with RA and was linked to upregulated expression of the chemokine CXCL1 and enhanced immune cell recruitment. In collagen-induced arthritis and SKG mouse models, prophylactic CXCL1 neutralization or lactate dehydrogenase inhibition reduced immune cell infiltration, alleviated joint inflammation, and mitigated bone destruction. Lactate dehydrogenase inhibition also reduced synovial lactate levels, histone lactylation, and CXCL1 expression. These findings support a role for histone lactylation in FLS-mediated immune cell recruitment and suggest that this pathway warrants further investigation as a therapeutic target in RA.
    Keywords:  CXCL1; fibroblast-like synoviocytes; histone lactylation; immune cell recruitment; rheumatoid arthritis
    DOI:  https://doi.org/10.1016/j.isci.2026.118108
  31. Front Cardiovasc Med. 2026 ;13 1941655
      Cardiovascular diseases (CVDs) continue to be leading causes of morbidity and death globally, with chronic inflammation contributing to disease progression and residual cardiovascular risk despite breakthroughs in conventional treatment. Immunometabolism, defined as the bidirectional connection of cellular metabolism and immune-cell activity, is an emerging approach for understanding the relationship between metabolic failure and cardiovascular inflammation. Several regulatory pathways, such as AMPK, mTOR, NLRP3, SIRT1, and NRF2, have been linked to metabolic and inflammatory responses in CVD. This review critically assesses the molecular evidence relating these pathways to CVD and investigates the potential for specific phytochemicals and phytomedicines to modify cardiovascular immunometabolism. Curcumin, resveratrol, berberine, quercetin, and andrographolide have all been shown to have pathway-specific effects in cellular and animal models of inflammation, oxidative stress, mitochondrial function, macrophage responses, and endothelial dysfunction. However, mechanistic activity should not be confused with demonstrated cardiovascular therapeutic effectiveness. Poor bioavailability, phytochemical variability, insufficient standardisation, pharmacokinetic uncertainty, possible herb-drug interactions, and a lack of sufficiently powered randomised clinical studies continue to impede translation. Future research should focus on standardised formulations, mechanistic validation in relevant cardiovascular models, pharmacokinetic and safety characterisation, and well-designed clinical trials combining immunometabolic biomarkers. The integration of multi-omics, systems pharmacology, nanophytomedicine, and computational techniques may help to advance evidence-based phytopharmaceutical development.
    Keywords:  cardiovascular disease; immunometabolism; inflammation; macrophage polarization; mitochondrial dysfunction; phytomedicine
    DOI:  https://doi.org/10.3389/fcvm.2026.1941655
  32. Mater Horiz. 2026 Nov 12.
      Chemical modification of an amino acid offers a route to tune its extracellular availability and downstream immune responses during tissue repair. Here, we esterified L-arginine with ethylene glycol, 1,3-propanediol, or 1,4-butanediol to obtain a series of hydrolysable arginine diesters (Arg-2, Arg-3, and Arg-4). Varying the two-, three-, and four-carbon linkers altered free-arginine release in PBS and serum and extracellular free-arginine availability in macrophage culture medium, with Arg-2 showing the fastest release among the diesters. Arg-y treatment increased STAT6 and arginase 1 expression, reduced nitric oxide production, and increased urea production in macrophages. Inhibition experiments support a contribution from STAT6 and arginase. Arg-2-conditioned macrophage medium enhanced tendonogenic transcript expression more strongly than direct Arg-2 exposure. Local intramuscular administration in a rat Achilles tendon rupture model reduced inflammatory infiltration and improved tendon matrix organization, maximum load, and gait recovery. These findings connect linker-dependent arginine availability with macrophage immunometabolism and tendon repair, supporting a materials-guided strategy for local tissue regeneration.
    DOI:  https://doi.org/10.1039/d6mh01455k
  33. Immunometabolism (Cobham). 2026 Oct;8(4): e00094
      Opposing metabolic perturbations of group 2 innate lymphoid cells (ILC2s) - such as upregulating or downregulating glycolysis and suppressing or preserving oxidative phosphorylation - repeatedly produce the same reduction in airway hyperreactivity. We argue that this does not reflect a contradiction in the literature, but rather a defining property of these cells: ILC2s are tissue-resident sentinels whose metabolism is calibrated by cell-surface receptor expression, local nutrient availability, microenvironmental conditions (such as oxygen tension and pH), and metabolic competition with neighboring immune cells, particularly the regulatory T (Treg) cells that restrain them. Since ILC2 pathogenicity requires the coordinated operation of both the glycolytic and oxidative arms, therapeutic interventions are effective in proportion to how much they restrict their metabolic plasticity rather than which specific pathway they target. Given that ILC2s co-localize with, and are likely to share their nutrient supply with, Treg cells and other neighboring populations, this distinction has major clinical implications; it separates targeted therapies that selectively disarm the effector from nonselective strategies that starve the effector and its suppressor together.
    Keywords:  airway hyperreactivity; group 2 innate lymphoid cell; immunometabolism; metabolic flexibility; programmed cell death protein 1 agonism; regulatory T cells
    DOI:  https://doi.org/10.1097/IN9.0000000000000094
  34. Nat Commun. 2026 11 06. pii: 11497. [Epub ahead of print]17(1):
      Neutrophil extracellular trap formation is a central innate immune defence mechanism that depends on NADPH oxidase-driven reactive oxygen species production. How NADP⁺ availability is regulated during neutrophil activation remains unclear. Using integrated lipidomic, biochemical and functional analyses in human neutrophils, we identify NAD kinase, the sole enzyme responsible for NADP⁺ synthesis, as a direct lipid-regulated effector downstream of phospholipase D1. Neutrophil activation induces rapid, phospholipase D1-dependent production of phosphatidic acid and phosphatidylinositol 4,5-bisphosphate, which bind and activate NAD kinase. The resulting cytosolic NADP⁺ is reduced to NADPH by the oxidative pentose phosphate pathway and consumed by NADPH oxidase during neutrophil extracellular trap formation. Pharmacological or genetic disruption of phospholipase D1 suppresses NAD kinase activity, depletes NADP⁺ and impairs neutrophil extracellular trap formation independently of direct NADPH oxidase inhibition. These findings define a lipid-metabolic axis coupling phospholipase D1-driven membrane remodelling to NADP⁺ availability and innate immune function.
    DOI:  https://doi.org/10.1038/s41467-026-79319-6
  35. Int J Mol Sci. 2026 Oct 28. pii: 9666. [Epub ahead of print]27(21):
      Obesity reshapes immune function across adipose tissue, circulation, and hematopoietic compartments. Weight reduction improves cardiometabolic health, yet emerging evidence indicates that prior obesity can leave persistent cellular, transcriptional, and epigenetic changes. Whether nutrition can reverse this biological imprint remains uncertain. We conducted a critical narrative review informed by structured searches of PubMed/MEDLINE, the Cochrane Library, and Epistemonikos, complemented by backward and forward citation tracking. We prioritized mechanistic human studies, controlled dietary interventions, longitudinal weight-loss studies, and experiments that tested persistence after stimulus withdrawal or response to re-exposure. Evidence was interpreted according to biological compartment and study design rather than pooled statistically. Obesogenic exposures can alter innate immune metabolism, inflammasome signaling, hematopoiesis, and chromatin states. Animal studies provide the strongest evidence that these changes can persist after weight normalization and amplify responses during weight regain. Human studies show incomplete normalization of adipose immune states, persistent adipocyte programs, and durable methylation changes in T lymphocytes after weight loss. Dietary interventions can lower inflammatory tone and modify immune metabolism, microbial metabolites, and lipid mediator pathways, but no dietary pattern has been shown to erase established obesity-associated immune memory in humans. An evidence map built on a core set of 47 studies showed that experimental work dominates the induction, persistence and re-challenge domains, whereas human evidence clusters in post-weight-loss remodelling and dietary modulation; human re-challenge data were absent and no study provided a direct test of reversal in humans. Obesity-associated immunometabolic memory appears to be distributed across hematopoietic, immune, adipose, stromal, and microbial compartments. Nutrition can modulate mechanisms implicated in this persistence, but human evidence of reversal is lacking, and whether pharmacologically induced weight loss leaves a comparable imprint has not been tested. Mechanistic trials should separate energy deficit, diet composition, adiposity change, and weight-loss modality and include a weight-stable follow-up and functional re-challenge where feasible.
    Keywords:  adipose tissue; epigenetic memory; immunometabolism; inflammation; nutrition; obesity; trained immunity; weight loss
    DOI:  https://doi.org/10.3390/ijms27219666
  36. Free Radic Biol Med. 2026 Nov 12. pii: S0891-5849(26)01273-6. [Epub ahead of print]
       BACKGROUND: Hepatic ischemia-reperfusion injury (HIRI) is a major cause of early graft dysfunction and postoperative liver injury, yet effective mechanism-based therapies remain limited. Macrophage metabolic reprogramming and ferroptosis-associated injury have emerged as important contributors to HIRI. Pyruvate kinase M2 (PKM2), a key regulator of glycolytic metabolism, coordinates cellular metabolic states through dynamic changes in its oligomeric configuration. However, its role in hepatic macrophages during HIRI remains incompletely understood.
    OBJECTIVES: This study investigated whether PKM2 remodeling contributes to metabolic reprogramming and ferroptosis-associated injury in hepatic macrophages during HIRI and evaluated the therapeutic potential of targeting this pathway.
    METHODS: PKM2 expression, phosphorylation, oligomeric state, and subcellular redistribution were analyzed in human liver grafts, murine HIRI models, and primary hepatic macrophages subjected to hypoxia/reoxygenation (H/R). TEPP-46 was used to stabilize PKM2 tetramers. Liver injury, glycolytic metabolism, oxidative stress, lipid peroxidation, ferroptosis-associated molecular changes, glycolytic signatures, and stimulator of interferon genes (STING)/nuclear receptor coactivator 4 (NCOA4)-related signaling were assessed in vivo and in vitro.
    RESULTS: PKM2 was markedly upregulated during HIRI and showed increased Y105 phosphorylation and nuclear accumulation, with hepatic macrophages representing a major responsive population. Systemic TEPP-46 treatment promoted PKM2 tetramer formation, limited nuclear PKM2 accumulation, and attenuated liver injury in vivo. In hepatic macrophages, PKM2 tetramer stabilization restrained glycolytic reprogramming, reduced ATP production, dampened STING/NCOA4-associated signaling, and alleviated ferroptosis-associated oxidative and molecular changes after H/R, including reactive oxygen species (ROS) accumulation, lipid peroxidation, iron overload, and disruption of GPX4-related antioxidant defenses. Pretreatment with dimethyl fumarate or 2-deoxy-D-glucose also mitigated liver injury and suppressed ferroptosis-associated oxidative changes in murine HIRI.
    CONCLUSIONS: These findings suggest that PKM2 remodeling in hepatic macrophages contributes to glycolytic reprogramming and ferroptosis-associated redox stress during HIRI, whereas pharmacological stabilization of PKM2 tetramers alleviates liver injury by restraining this metabolic shift and dampening STING/NCOA4-associated ferroptotic signaling. Targeting PKM2-centered immunometabolic remodeling may represent a potential therapeutic strategy for HIRI.
    Keywords:  Ferroptosis; Glycolytic reprogramming; Hepatic ischemia-reperfusion injury; Hepatic macrophages; PKM2; Redox signaling
    DOI:  https://doi.org/10.1016/j.freeradbiomed.2026.11.022
  37. Clin Exp Immunol. 2026 Nov 10. pii: uxag075. [Epub ahead of print]
      Cellular metabolism is now recognised as an active regulator of immune cell activation, differentiation, and function. However, much of this conceptual framework derives from in vitro systems and animal models that may not fully reproduce human physiology or disease. Many studies of human immune metabolism are constrained by artificial culture conditions, tissue dissociation, limited pathway coverage, and a reliance on static measurements that do not directly quantify metabolic flux in vivo. Interpretation is further complicated by the use of blood samples as a surrogate for diseases that arise in specialised tissues, such as synovium, gut, and skin, and by the influence of systemic physiology, including hepatic substrate regulation, adipose tissue, endocrine and neuronal signalling, and the gut microbiota. In this review, we examine what current experimental approaches can infer about immune metabolism in humans, with a focus on immune-mediated inflammatory diseases. Oncology provides a valuable methodological precedent through its use of tissue sampling, spatial profiling, and stable isotope tracing, while also illustrating the challenges of assigning metabolic activity to individual cell populations within heterogeneous tissues. We propose five priorities for the field: move beyond blood to inflammatory tissue; complement static abundance with dynamic, stable isotope flux analysis; integrate single cell, spatial, and imaging modalities; incorporate carefully designed human metabolic perturbations; and account for the wider systemic and pre-analytical context. The next phase of human immunometabolism should move from pathway annotation in reductionist models towards dynamic, tissue-resolved, and clinically anchored studies of immune cell metabolism in vivo.
    Keywords:  Immunometabolism; immune-mediated inflammatory diseases; metabolic flux; spatial metabolomics; stable isotope tracing
    DOI:  https://doi.org/10.1093/cei/uxag075
  38. Nat Rev Immunol. 2026 Nov 13.
      Dendritic cells (DCs) orchestrate immune responses, and metabolic processes act as key checkpoints underlying their function. In this Review, we summarize how metabolism shapes DC biology, including in different disease settings. We first discuss the effects of metabolic programmes on the immunogenic and tolerogenic functions of DCs. Then, we discuss the roles of extracellular nutrients and metabolites in orchestrating intracellular signalling in DCs, as well as their effects on the bidirectional metabolic interactions between DCs and the local tissue microenvironment. Additionally, we describe how metabolism governs DC function in the settings of cancer, autoimmunity and metabolic disorders and conclude with a discussion on key future directions for the field. Understanding the metabolic processes that dictate DC function holds strong translational potential for the treatment of immune-mediated diseases.
    DOI:  https://doi.org/10.1038/s41577-026-01368-1
  39. EMBO Rep. 2026 Nov 07.
      Cellular metabolism supports all viral replication steps, and the metabolic state of infected cells is a key factor influencing viral infections. Human Immunodeficiency virus (HIV) remains latent in resting CD4 T lymphocytes but actively replicates in activated CD4 T cells, in part due to enhanced energy metabolism. Here, using the recently developed Human Plasma-Like Medium (HPLM) that mimics the physiological plasma concentration of metabolites, we investigate how this near-physiologic environment modulates HIV-1 infection in primary CD4 T cells. Compared to the conventional culture medium (RPMI), HPLM enhances HIV-1 infection in CD4 T cells despite similar levels of cellular activation, proliferation and expression of viral receptors. In contrast with previous studies using RPMI, HPLM increases infection while decreasing energy metabolism and affecting other non-energetic metabolic pathways. By adjusting levels of several metabolites in RPMI and HPLM, we uncover that the amino acid balance rather than energy metabolism favours HIV-1 replication in this system. Overall, our study uses near-physiological conditions to better define metabolic dependencies of viral infections and highlights non-energetic metabolism pathways important for HIV-1 infection.
    DOI:  https://doi.org/10.1038/s44319-026-00976-1
  40. Cells. 2026 Oct 27. pii: 1950. [Epub ahead of print]15(21):
      Aging is accompanied by a progressive disruption of brain homeostasis, yet the molecular mechanisms underlying this age-associated deterioration remain poorly understood. Microglia play a critical role in maintaining brain homeostasis by clearing cellular debris and neurotoxic protein aggregates. Here, we investigated the effects of methylglyoxal (MG), a highly reactive endogenous metabolite that accumulates with aging, on microglial functions using the murine microglial cell line BV2. We assessed the effects of MG exposure on multiple aspects of microglial biology in both control and bacterial lipopolysaccharide (LPS)-treated cells, including phagocytic activity, cellular proliferation, cytokine secretion, mitochondrial bioenergetics, mitochondrial membrane potential, and intracellular and mitochondrial reactive oxygen species. We found that MG significantly impaired mitochondrial bioenergetics, leading to reduced cellular energy production, and markedly suppressed multiple essential microglial functions, including phagocytosis. Given the high reactivity of MG with arginine, we also investigated whether arginine depletion contributes to these functional impairments. Arginine depletion recapitulated the impairment of mitochondrial bioenergetics and microglial function induced by MG, demonstrating that arginine availability is a critical determinant of microglial metabolic fitness and immune function. These findings suggest that the age-associated accumulation of MG impairs mitochondrial bioenergetics and microglial functions, thereby potentially accelerating neurodegenerative processes.
    Keywords:  Alzheimer’s disease; brain homeostasis; methylglyoxal; microglia; mitochondrial bioenergetics; phagocytosis
    DOI:  https://doi.org/10.3390/cells15211950
  41. J Nanobiotechnology. 2026 Aug 19. pii: 1070. [Epub ahead of print]24(1):
      Pulmonary infections remain difficult to diagnose rapidly and non-invasively, as existing biomarkers lack both sensitivity and specificity. Here we present functionalized biomarker vesicles (FBVs), an inhalable nanotechnology platform that amplifies fractional exhaled nitric oxide (FeNO) in an infection-specific manner. FBVs are engineered from inactivated bacterial membranes and encapsulate L-arginine and NADPH, enabling selective uptake by M1-polarized macrophages within infected lung tissue. Upon phagocytosis or membrane fusion with iNOS-containing vesicles, FBVs release their payload to drive localized nitric oxide production, directly linking FeNO amplification to pathogen-induced immune activation. Optimized FBVs (800 nm) demonstrated efficient pulmonary delivery, robust macrophage uptake, and NO output tightly correlated with iNOS expression. In mouse infection models, FBV-induced FeNO distinguished infected from healthy with high accuracy (AUC = 0.94). In clinical bronchoalveolar lavage samples, FBV-based detection outperformed extracellular vesicle quantification, achieving superior diagnostic performance (AUC = 0.93). This strategy establishes a non-invasive diagnostic modality that couples host immune activation to measurable breath biomarkers, providing a direct path toward clinical translation for respiratory infection management.
    Keywords:  Fractional exhaled nitric oxide; Functionalized biomarker vesicles; Macrophages; Non-invasive diagnosis; iNOS
    DOI:  https://doi.org/10.1186/s12951-026-04942-w
  42. Yale J Biol Med. 2026 Sep;99(3): 442-451
      Viruses exploit mitochondrial biogenesis, dynamics, and mitophagy-complex processes that influence mitochondrial morphology, metabolism, and innate immune responses-to evade immunity, enhance replication, and facilitate infection. However, acute and nonacute viral infections induce mitochondrial dysfunction through distinct mechanisms. Unlike acute infections, nonacute viral infections dynamically regulate mitochondrial biogenesis by targeting key molecular pathways to support viral replication. Additionally, chronic infections promote mitochondrial fission either directly or indirectly by altering the expression of fission and fusion proteins. During acute infection, early mitophagy benefits viruses by removing damaged mitochondria, suppressing apoptosis, and fostering replication. In contrast, excessive or incomplete mitophagy in later nonacute stages may deplete cellular energy and impair mitochondrial function, ultimately triggering apoptosis and viral release. Consequently, therapies such as mitochondrial biogenesis modulators, mitophagy agonists, and mitochondria-targeted antioxidants could be effective against chronic viral infections. In this review, molecular mechanisms of nonacute viral mitochondrial remodeling are summarized, and corresponding regulatory approaches to enhance therapeutic outcomes are highlighted.
    Keywords:  apoptosis; fission; mitochondrial biogenesis; mitophagy; nonacute viral infections
    DOI:  https://doi.org/10.59249/SMXA2056
  43. iScience. 2026 Nov 20. 29(11): 117943
      Thyroid cancer (TC) incidence has risen globally, with advanced cases showing limited treatment options and poor prognosis. Claudin-1 (CLDN1), a tight junction protein, has context-dependent roles in cancer, but its function in TC remains unclear. Integrated bioinformatic analysis of TCGA and GEO datasets identified CLDN1 as a key hub gene upregulated in TC and associated with poor survival. Functional experiments demonstrated that CLDN1 knockdown suppressed TC cell proliferation, migration, and glycolytic metabolism, while its overexpression promoted these effects. Mechanistically, CLDN1 activated the TAp63 pathway, upregulating glycolytic enzymes (HK2, PKM2, and GLUT1) and enhancing glucose uptake, lactate production, and NADPH/NADP+ ratio. The glycolysis inhibitor 2-DG reversed CLDN1-driven oncogenic phenotypes in vitro and in vivo. In xenograft models, CLDN1 overexpression accelerated tumor growth, which was mitigated by 2-DG treatment. Collectively, CLDN1 drives TC progression by reprogramming glycolytic metabolism via the TAp63 pathway, suggesting the CLDN1-glycolysis axis as a potential therapeutic target for TC.
    Keywords:  CLDN1; TAp63 pathway; glycolysis; metabolic reprogramming; thyroid cancer
    DOI:  https://doi.org/10.1016/j.isci.2026.117943
  44. Front Microbiol. 2026 ;17 1975307
      Critical illness can profoundly disturb the intestinal microbiota-metabolite-host immune axis through the combined effects of shock, hypoxia, altered nutritional intake, antimicrobial exposure, organ dysfunction, and impaired epithelial barrier integrity. These changes can reshape microbial metabolic capacity, host co-metabolism, and systemic metabolite exposure, while the host may simultaneously exhibit overlapping features of hyperinflammation, immune tolerance, lymphocyte dysfunction, impaired antimicrobial defense, and tissue repair. Metabolites generated through microbial metabolism or shared microbial-host pathways may therefore contribute to immune reprogramming, although their effects are highly context dependent and cannot be regarded as uniformly beneficial or detrimental. This narrative review examines short-chain fatty acids, tryptophan-derived indoles, secondary bile acids, succinate, lactate, trimethylamine N-oxide, polyamines, and aromatic metabolites, with particular attention to source attribution, anatomical compartment, host co-metabolism, receptor signaling, and their potential influence on antimicrobial immunity. These metabolites may act through G-protein-coupled receptors, AhR, PXR, FXR, TGR5, VDR, HIF-1α, inflammasome pathways, mitochondrial signaling, and epigenetic mechanisms to modulate macrophages, neutrophils, dendritic cells, innate lymphoid cells, T lymphocytes, epithelial barriers, and endothelial responses. The direction and magnitude of these effects are likely to vary according to timing, concentration, anatomical compartment, immune-cell state, pathogen burden, and renal or hepatic clearance. Within this framework, attenuation of inflammatory signaling may help limit early collateral tissue injury, yet the same response could become disadvantageous when antimicrobial competence is already impaired. Similarly, succinate and lactate may reflect or contribute to distinct inflammatory, regulatory, or reparative programs depending on whether they arise from microbial or host metabolism and whether they act within intracellular or extracellular compartments. Human studies in critically ill populations have linked dysbiosis and metabolomic alterations with secondary infection, prolonged organ support, and mortality; however, most have not been able to resolve microbial source attribution or establish causal mediation. Future work would therefore benefit from integrating longitudinal microbiome, metabolome, immune-function, and organ-clearance measurements with source-resolved approaches, including isotope tracing, as well as state-specific and trajectory-informed clinical endpoints. Microbiome-directed interventions may be most appropriately investigated as context-dependent modulators of host defense rather than as broadly anti-inflammatory strategies.
    Keywords:  critical illness; gut microbiota; host–microbiota interactions; immune reprogramming; immunometabolism; microbial–host co-metabolism; sepsis; source attribution
    DOI:  https://doi.org/10.3389/fmicb.2026.1975307
  45. Front Immunol. 2026 ;17 1950688
      Transition metals such as iron, zinc, and copper serve as indispensable cofactors in immunometabolic regulation. As central regulators of innate immunity, macrophages rely on strict metal homeostasis to maintain their functional plasticity. Studies have shown that transition metal dyshomeostasis is associated with aberrant macrophage polarization and sustained inflammatory responses. Such macrophage dysfunction may contribute to the initiation and progression of chronic systemic metabolic diseases. This review comprehensively summarizes the regulatory functions of essential transition metals in shaping macrophage inflammatory phenotypes and regulating metabolic reprogramming. We further clarify the molecular mechanisms by which metal-induced macrophage dysfunction participates in the pathogenesis of major metabolic diseases such as type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and atherosclerosis. We discuss how targeting intracellular metal homeostasis via selective metal chelators and novel metal-based nanomaterials represents a promising and innovative immunomodulatory therapeutic strategy. Essential transition metal homeostasis is a critical determinant of macrophage plasticity and appears to play a significant role in the pathogenesis of chronic metabolic diseases. Macrophage dysfunction induced by transition metal dyshomeostasis is associated with systemic insulin resistance and may contribute to tissue-specific damage within hepatic, vascular, and adipose microenvironments. Although the mechanistic foundations have been established, significant knowledge gaps remain regarding stage-specific variations and dose-dependent thresholds of metal-induced macrophage phenotypic shifts. Future research should prioritize the validation of metal-based biomarkers in clinical cohorts and the development of targeted 'metal-homeostasis' therapies to restore macrophage function, thereby providing a novel theoretical framework for the prevention and treatment of chronic metabolic disorders.
    Keywords:  iron; macrophage polarization; metabolic diseases; metal homeostasis; zinc
    DOI:  https://doi.org/10.3389/fimmu.2026.1950688
  46. Int J Mol Sci. 2026 Oct 28. pii: 9637. [Epub ahead of print]27(21):
      Zika virus (ZIKV) substantially relies on host lipid metabolism, presenting a prime target for host-directed antivirals. To identify host-directed antiviral interventions while circumventing interferon-mediated transcriptomic masking, we curated a dual-virus (dengue and ZIKV) gene signature to query the Connectivity Map. Top lipid-lowering candidates were validated using a reporter virus (rZIKV-Venus) and an authentic wild-type (WT) ZIKV in Vero E6 cells-a model deliberately selected for its interferon deficiency to isolate pure metabolic responses. Dose-response screening of 67 prioritized compounds identified atorvastatin, rosuvastatin, and clofibrate as potent ZIKV inhibitors. Statin-clofibrate combinations exhibited strong synergy, with fractional inhibitory concentration index (FICI) values of 0.203 (atorvastatin-clofibrate) and 0.117 (rosuvastatin-clofibrate) for the 4:1 clofibrate-to-statin ratio and an optimized selectivity index. Mechanistically, exogenous oleic acid supplementation induced significant metabolic complementation, significantly restoring both host lipid droplet (LD) abundance and ZIKV replication readouts suppressed by the dual treatment. Relative LD intensity strongly correlated with viral intensity in both models (Pearson r = 0.951 and 0.956, respectively; both p < 0.0001). These findings demonstrate that concurrent pharmacological modulation of host lipid metabolism exerts synergistic anti-ZIKV effects, highlighting highly curated transcriptomic repurposing as a mechanistic prioritization strategy for host-directed antiviral discovery.
    Keywords:  Zika virus; clofibrate; dengue virus; drug repurposing; host-directed antiviral; immunometabolism; lipid droplet; metabolic complementation; statin
    DOI:  https://doi.org/10.3390/ijms27219637
  47. Biomed Pharmacother. 2026 Nov 11. pii: S0753-3322(26)01087-5. [Epub ahead of print]205 120051
      Natural killer (NK) cells are critical mediators of immune surveillance, yet their functional capacity is frequently compromised by chronic metabolic and environmental stress. Although metabolic reprogramming is recognized as a major determinant of NK-cell activity, how metabolic capacity is coordinated with translational control to sustain effector function and cellular persistence remains poorly understood. This review examines NK-cell fitness as a dynamic metabolic-translational balance in which nutrient availability, mitochondrial function, redox homeostasis, and nutrient-sensing pathways determine the resources available for biosynthesis, while translational control regulates their allocation toward effector protein production, adaptation, and cellular maintenance. We highlight eukaryotic elongation factor-2 kinase (eEF2K) as a mechanistically defined regulator of translational elongation with direct evidence of relevance to NK-cell function, while Nucleus Accumbens-Associated Protein 1 (NAC1) is considered a candidate regulator of NK-cell metabolic adaptation whose role remains to be established. We propose that the interaction between metabolic capacity and translational demand may determine whether NK cells maintain function or become dysfunctional under persistent stress. This framework provides a rationale for engineering NK cells with greater metabolic-translational reserve and resilience to metabolically restrictive tumor microenvironments, with potential implications for improving the persistence and therapeutic efficacy of adoptive and CAR-NK cell therapies.
    Keywords:  Chronic inflammation; EEF2k; Metabolic fitness; NAC1; NK cell; Translational control; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.biopha.2026.120051
  48. Hemasphere. 2026 Nov;10(11): e70521
      Exposure of macrophages to iron has been implicated in sterile inflammation through reactive oxygen species (ROS)-dependent cell pro-inflammatory activation. Here, we compare the effect of the commonly used oral iron salt, iron sulfate (FeSO4), with that of an innovative formulation, sucrosomial® iron (SI), on the iron status and inflammatory activation of tissue macrophages in mice with iron-deficiency (ID) anemia. Despite similar recovery of anemia and tissue ID, FeSO4 treatment, but not SI, elevated transferrin saturation, generated non-transferrin bound iron (NTBI), and quickly corrected macrophage ID compared to SI, with a more pronounced cell transferrin receptor 1 (TfR1) suppression and labile iron pool expansion. In both ex vivo and in vitro ID macrophages, the rapid kinetic of ID correction by FeSO4 was associated with increased ROS and inflammatory cytokine production, whereas these responses were minimally affected by the slower kinetic of SI uptake. Metabolome data suggest that FeSO4 but not SI suppressed lipid metabolism in macrophages, indicating reduced fatty acid β-oxidation and limited reliance on mitochondrial activity, metabolic hallmarks of cell inflammatory skewing. Ultimately, we demonstrate that FeSO4 drives a higher autocrine production of hepcidin compared to SI, via inflammatory cytokine-mediated activation of the STAT3 signaling pathway, further limiting macrophage iron recycling in ID. In conclusion, our data prove that the kinetic of macrophage ID correction by iron formulations determines cell inflammatory activation and modulates hepcidin production. Overall, SI appears a superior formulation than FeSO4 due to its reduced pro-oxidant potential, inflammatory action, and hepcidin induction, with relevance for ID treatment in individuals with pre-existing inflammatory conditions.
    DOI:  https://doi.org/10.1002/hem3.70521
  49. Immunol Res. 2026 Nov 12. pii: 141. [Epub ahead of print]74(1):
      Obesity is a chronic immunometabolic disorder associated with alterations in biological aging pathways and increased risks of type 2 diabetes mellitus, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, neurodegeneration, and cancer. Obesity and chronological aging share several characteristics, including low-grade inflammation, cellular senescence, mitochondrial dysfunction, oxidative stress, epigenetic alterations, and immune remodeling. However, these similarities do not necessarily establish accelerated biological immune aging. This review critically evaluates obesity-associated immunosenescence, metaflammation, and multiorgan dysfunction by examining supporting and conflicting findings, alternative explanations, methodological limitations, and therapeutic evidence. Although experimental and observational studies report alterations in lymphocyte differentiation, innate immune function, inflammatory signaling, and selected biological-age markers, these findings are not uniformly observed across immune-cell populations, tissues, or metabolic phenotypes. Metabolically healthy obesity, tissue-dependent epigenetic aging, and differences between human and animal findings challenge the interpretation of obesity as a universal accelerator of immunosenescence. Furthermore, chronological age, cytomegalovirus infection, sex-related differences, adiposity distribution, and metabolic comorbidities complicate attributing immune alterations specifically to obesity. The proposed immunosenescence-metaflammation-multiorgan dysfunction framework therefore remains a testable mechanistic hypothesis rather than an established causal pathway. Although immune-cell phenotypes, epigenetic clocks, inflammatory mediators, and multi-omics signatures may help characterize obesity-associated immune dysfunction, their specificity, longitudinal validity, and clinical utility remain insufficiently established. Nutritional interventions, exercise, bariatric surgery, and pharmacological treatments can improve selected metabolic and inflammatory outcomes, but these improvements do not necessarily demonstrate sustained reversal of biological immune aging. By critically comparing supportive evidence with contradictory observations and unresolved causal relationships, this review identifies the principal limitations of current mechanistic, biomarker, and therapeutic research. Future studies should prioritize longitudinal immune profiling, direct functional assessment, tissue- and sex-specific analyses, causal validation, and controlled interventions incorporating validated immune-aging endpoints to determine whether premature immune aging is a measurable and therapeutically modifiable consequence of obesity.
    Keywords:  Biological aging; Cellular senescence; Immune aging; Immunometabolism; Immunosenescence; Metaflammation; Obesity; Precision medicine
    DOI:  https://doi.org/10.1007/s12026-026-09877-w
  50. BMC Microbiol. 2026 Aug 13. pii: 989. [Epub ahead of print]26(1):
      Inflammatory bowel disease (IBD) involves dysregulated host immunity, gut microbial dysbiosis, and metabolic disturbances. As key innate immune cells, macrophages play critical roles in inflammatory responses, epithelial barrier dysfunction, and host-microbiota interactions. Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a key adaptor protein in pro-inflammatory signaling, but the role of macrophage TRAF6 in colitis-associated microbial and metabolic alterations remains unclear. Here, we used macrophage-specific Traf6 conditional knockout mice in a 3% DSS-induced colitis model. TRAF6 expression was increased in colonic tissues from DSS-treated mice and patients with IBD, with enhanced co-localization with CD68-positive macrophages. Macrophage-specific Traf6 deletion reduced colitis severity, inflammatory responses, and epithelial barrier injury. 16S rRNA gene sequencing showed substantial gut microbiota remodeling, including reduced Enterococcus abundance. Untargeted metabolomics identified alterations in arachidonic acid metabolism: prostaglandin A2 (PGA2) was significantly reduced in both fecal and serum samples, whereas 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid [12(S)-HHT] was significantly reduced in feces and showed a similar downward trend in serum. Enterococcus abundance was positively associated with PGA2 and 12(S)-HHT levels, and an independent human IBD cohort further showed enrichment of Enterococcus. Collectively, macrophage-specific Traf6 deletion ameliorated DSS-induced colitis and was associated with coordinated remodeling of the gut microbiota and host metabolism, supporting an association between macrophage TRAF6, reduced Enterococcus abundance, and altered arachidonic acid metabolism during intestinal inflammation.
    Keywords:   Enterococcus ; Arachidonic acid metabolism; DSS-induced colitis; Macrophages; TRAF6
    DOI:  https://doi.org/10.1186/s12866-026-05536-0
  51. Hum Vaccin Immunother. 2026 Dec;22(1): 2753297
      Extracellular adenosine is a major immunosuppressive metabolite of the tumor microenvironment and a key barrier to anti-tumor immunity. Generated from ATP by the ectonucleotidases CD39 and CD73, it signals mainly through the high-affinity A2A adenosine receptor (A2AR). Although A2AR is regarded as an inhibitory immune checkpoint, recent work shows that its functions extend beyond immediate effector suppression to the regulation of metabolic fitness, mitochondrial homeostasis, and CD8+ T-cell differentiation. Notably, both sustained A2AR activation and complete receptor deficiency can drive terminal exhaustion through distinct mechanisms, and CD73 and extracellular adenosine are not biologically equivalent. Here we summarize adenosine signaling, the cell-specific roles of the A2AR axis, and the clinical development of A2AR-targeting immunotherapies. We identify the principal obstacles to therapeutic translation and advance biomarker-guided, calibrated modulation of A2AR signaling as a testable hypothesis rather than an established therapeutic principle, one that now requires comparative exposure-response and longitudinal intervention studies.
    Keywords:  A2AR; Adenosine; CD73; CD8+ T-cell exhaustion; cancer immunotherapy; immunometabolism; tumor microenvironment
    DOI:  https://doi.org/10.1080/21645515.2026.2753297
  52. Cancer Immunol Res. 2026 Nov 13.
      Malignant ascites is a lipid-rich, immunosuppressive environment that has recently emerged as a target for locoregional bispecific T-cell engager (BiTE) therapy. However, the mechanisms by which ascites, particularly its lipid components, suppress antitumour immunity and limit therapeutic efficacy remain poorly understood. Here, we investigated the impact of ascites lipids on T-cell immunosuppression and assessed whether lipid modulation could enhance the efficacy of BiTE therapy. Transcriptomic profiling of T cells exposed to acellular ascites fluid revealed an enriched signature associated with cholesterol efflux and incomplete fatty acid oxidation, which are metabolic features often found in exhausted T cells. These alterations converged on a metabolically imbalanced state linked to impaired plasma membrane signalling. Meanwhile, anti-CD3/CD28-stimulated T cells showed marked lipid accumulation in ascites, which was attenuated by lipid depletion. Functionally, lipid removal was associated with enhanced TCR-associated signalling, as demonstrated by increased ZAP70 phosphorylation, and restored CD137 expression while leaving CD25 unchanged. To determine whether ascites lipids also affected BiTE efficacy, T cells were cocultured with ovarian cancer cells and an EpCAM-targeting BiTE in untreated or lipid-depleted ascites. Ascites suppressed BiTE-mediated T-cell activation and abolished tumour cell killing, whereas lipid depletion contributed to the restoration of T-cell activation, IFN-γ production and BiTE-mediated cytotoxicity. Together, these findings suggest that lipids contribute to T-cell dysfunction in ovarian cancer ascites and demonstrate that lipid depletion is associated with restored antitumour T-cell activity. Targeting this metabolic barrier may therefore provide a combination strategy to potentiate BiTE therapy in malignant ascites.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-26-0206
  53. Front Microbiol. 2026 ;17 1996310
      Fusobacterium, especially Fusobacterium nucleatum, has emerged as a metabolically active pathobiont that can affect host physiology and disease pathogenesis. Through its ability to produce and regulate various metabolites, Fusobacterium can shape immune response, cellular metabolism, and disease progression. Short-chain fatty acids (SCFAs), being part of Fusobacterium-associated metabolic changes observed during disease, are involved in microbial cross-feeding and can affect neutrophil recruitment and inflammatory signaling through free fatty acid receptors. In the case of colorectal cancer (CRC), Fusobacterium-derived metabolites can impact tumor and immune cell phenotype via a number of mechanisms, including aryl hydrocarbon receptor (AhR) activation via indole derivatives, inflammatory and metabolic signaling via hydrogen sulfide, as well as an increase in Glucose transporter 1 (GLUT1) expression, lactate production, and histone lactylation via formate-related metabolites. Besides, F. nucleatum can reshape tumor-cell metabolism, including cholesterol biosynthesis through miR-130a-3p-mediated inhibition of AMP-activated protein kinase (AMPK) signaling, whereas butyrate has been reported to counteract this metabolic phenotype in experimental CRC models. In addition, F. nucleatum-associated succinate has been shown to suppress cGAS-Interferon beta (IFN-β) signaling, thereby reducing antitumor immune activation, impairing CD8+ T-cell trafficking, and promoting immune escape and resistance to anti-Programmed Cell Death Protein 1 (PD-1) therapy. The present review provides an overview of current understanding of the biological roles of Fusobacterium-derived metabolites, focusing on SCFAs, succinate, indole derivatives, hydrogen sulfide, and formate-related metabolites.
    Keywords:  Fusobacterium nucleatum; colorectal cancer; immunomodulation; indole-derived compounds; microbial metabolites; short-chain fatty acids; succinate
    DOI:  https://doi.org/10.3389/fmicb.2026.1996310
  54. Tissue Cell. 2026 Nov 10. pii: S0040-8166(26)00843-8. [Epub ahead of print]105 104147
       BACKGROUND AND AIMS: Exercise is associated with reduced intestinal inflammation, but the immunometabolic mediators linking physical activity to mucosal immune regulation remain incompletely defined. Exercise-associated metabolomic profiling identified the serotonin-derived metabolite 5-hydroxyindoleacetic acid (5-HIAA) as a potential bioactive mediator. We therefore investigated whether 5-HIAA could inhibit macrophage NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-dependent pyroptosis and reproduce selected protective effects of exercise against experimental colitis.
    METHODS: Prior to dextran sulfate sodium (DSS) administration, mice were subjected to a treadmill exercise preconditioning regimen. Untargeted metabolomics was used to identify exercise-associated metabolic changes in colonic tissue. The protective effects of exogenously administered 5-HIAA were further investigated in a DSS-induced colitis model and LPS/nigericin-induced pyroptosis models in THP-1-derived macrophages and primary bone marrow-derived macrophages. Aryl hydrocarbon receptor (AHR) silencing in vitro and systemic administration of AAV-F4/80-shAhr in vivo were used to investigate the involvement of AHR in the effects of 5-HIAA.
    RESULTS: Exercise preconditioning alleviated DSS-induced colitis and was associated with a distinct colonic metabolic profile in which 5-HIAA showed higher relative abundance. Exogenous 5-HIAA reproduced several protective phenotypes of exercise, including reduced body-weight loss, preserved colon length, improved mucosal histology, lower pro-inflammatory cytokine concentrations, and reduced macrophage-associated interleukin-1β (IL-1β) staining. In macrophages, 5-HIAA attenuated NLRP3 inflammasome activation and pyroptotic membrane damage, as indicated by reduced caspase-1 cleavage, gasdermin D (GSDMD) processing, lactate dehydrogenase (LDH) release, and propidium iodide (PI) uptake. AHR silencing weakened the anti-pyroptotic effects of 5-HIAA in vitro. Systemic administration of AAV-F4/80-shAhr attenuated its protective effects against colitis, although the efficiency and cellular specificity of silencing were not directly validated.
    CONCLUSIONS: These findings identify 5-HIAA as an exercise-associated candidate immunometabolite and support an AHR-dependent mechanism through which 5-HIAA restrains NLRP3 inflammasome-associated pyroptotic responses in macrophages.
    Keywords:  5-hydroxyindoleacetic acid; Aryl hydrocarbon receptor; Exercise; Experimental colitis; Macrophage pyroptosis
    DOI:  https://doi.org/10.1016/j.tice.2026.104147
  55. Mol Biol Rep. 2026 Nov 10. pii: 1940. [Epub ahead of print]53(1):
      Hepatocellular carcinoma (HCC) develops within a metabolically constrained and immunologically heterogeneous tumor microenvironment in which malignant, stromal, and immune cells compete for nutrients and exchange bioactive metabolites. Ceramide is a main sphingolipid intermediate and signaling lipid with several biological effects, which depend on acyl-chain composition, subcellular localization, metabolic flux, and cellular context. Sphingomyelin phosphodiesterase 3 (SMPD3), also known as neutral sphingomyelinase 2 (nSMase2), generates ceramide through sphingomyelin hydrolysis and also participates in extracellular-vesicle biogenesis. HCC-specific findings claimed that reduced SMPD3 expression could be associated with adverse clinicopathological features and suppression of malignant phenotypes after SMPD3 restoration, could be in favor of a tumor-restraining function. However, direct evidence that endogenous SMPD3-derived ceramide reprograms the metabolism of infiltrating immune cells in primary HCC is currently lacking. This review distinguishes HCC-specific findings from mechanistic evidence derived from tumor and inflammatory systems. We integrate ceramide biosynthesis and turnover, HCC immunometabolism, T-cell and myeloid-cell metabolic states, extracellular-vesicle communication, and therapeutic studies using ceramide nanoliposomes. We also discuss the context-dependent relationship between ceramide and apoptosis, autophagy, mitochondrial dysfunction, and ferroptosis, emphasizing that endogenous SMPD3-derived ceramide and exogenous short-chain ceramide formulations are not biologically interchangeable. Finally, we define experimental priorities required to test cell-specific SMPD3 functions, resolve ceramide species and spatial flux, validate biomarkers, and determine whether selective restoration of the SMPD3-ceramide axis can improve immunotherapy or other systemic treatment strategies in HCC.
    Keywords:  Ceramide; Hepatocellular carcinoma; Immunometabolism; Neutral sphingomyelinase 2; Sphingomyelin phosphodiesterase 3; Tumor microenvironment
    DOI:  https://doi.org/10.1007/s11033-026-13004-1
  56. Int J Mol Sci. 2026 Oct 29. pii: 9692. [Epub ahead of print]27(21):
      There is a growing recognition of obesity as a chronic immunometabolic disease in which impaired adipose tissue expandability contributes to a self-amplifying inflammatory network that extends across multiple organs. This state-of-the-art narrative review, the third and final part of the Prometheus's Fire series, considers how lifestyle interventions, bariatric surgery and pharmacological therapies may disrupt this network and support the restoration of immunometabolic homeostasis. We introduce the concept of therapeutic convergence, describing how interventions with different primary mechanisms can influence shared processes, including NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome activity, adipokine dysregulation, adipose tissue remodelling, mitochondrial stress and inter-organ inflammatory signalling. Evidence from randomised controlled trials, meta-analyses and mechanistic studies shows that these interventions differ considerably in the extent and breadth of their effects. Bariatric surgery, glucagon-like peptide-1 (GLP-1) receptor agonists and double GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (tirzepatide) have the most consistent evidence for coordinated effects on adipose tissue inflammation, metabolic dysfunction and inter-organ signalling. Other interventions appear to influence more selected components of the network and may therefore have greater value as complementary rather than comprehensive approaches. This perspective also highlights a limitation of relying on body weight as the primary measure of therapeutic success. Weight loss remains an important clinical goal, but it may not fully reflect the extent or durability of immunometabolic recovery. The therapeutic convergence framework therefore offers a way to understand how mechanistically distinct interventions can produce overlapping systemic benefits and may help identify treatment strategies that more effectively restore adipose tissue function while disrupting the inflammatory processes that sustain metabolic disease.
    Keywords:  GLP-1 receptor agonists; Mediterranean diet; NLRP3 inflammasome; SGLT2 inhibitors; adipose tissue immunometabolism; bariatric surgery; caloric restriction; metformin; obesity; tirzepatide
    DOI:  https://doi.org/10.3390/ijms27219692
  57. iScience. 2026 Nov 20. 29(11): 118126
      Obesity-associated adipose tissue dysfunction involves coordinated immune and metabolic remodeling. Using single-nucleus RNA sequencing of human visceral white adipose tissue, we identified an obesity-enriched LGMN-high macrophage state with increased GRN expression and predicted PGRN-SORT1 signaling toward adipocytes. In macrophage-adipocyte co-culture systems, LGMN knockdown reduced macrophage PGRN abundance and enhanced adipocyte lipolysis-related signaling, whereas recombinant PGRN attenuated these effects in a SORT1-dependent manner. In high-fat diet-fed mice, AAV-mediated Lgmn knockdown reduced PGRN-SORT1 signaling, increased lipolysis-related protein levels, and improved adiposity, glucose homeostasis, circulating lipids, and inflammatory markers. These findings support an LGMN-PGRN-SORT1 macrophage-adipocyte communication axis linking obesity-associated myeloid remodeling to altered adipocyte lipid metabolic programs.
    Keywords:  high-fat diet; legumain; macrophage; obesity; progranulin; sortilin 1
    DOI:  https://doi.org/10.1016/j.isci.2026.118126